| Name | Title | Contact Details |
|---|
Club Champion is a premier golf club fitting company founded in 2010 and based in Willowbrook, Illinois. With over 140 locations across the United States, Canada, the UK, and Australia, the company specializes in custom golf club fitting and building services. Their goal is to enhance golfers performance by providing tailored solutions that deliver longer and more accurate shots based on individual swing characteristics. The company offers unbiased, tour-quality fittings with access to a vast selection of over 50,000 to 65,000 clubhead, shaft, and grip combinations from more than 65 brands. Each fitting session typically lasts around three and a half hours and utilizes advanced technology, including TrackMan launch monitors and SAM PuttLab systems, to ensure precise measurements. Club Champion assembles custom golf clubs in a centralized facility near Chicago, catering to a diverse clientele that includes both amateur and professional golfers. With a commitment to quality and performance, Club Champion conducts over 100,000 fittings annually, making high-quality custom fitting accessible to a wide range of players.
VFO LLC provides accounting and finance services to early stage start-up companies in any industry. From day-to-day bookkeeping activity to financial forecasts.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.